Maple Gioia
About Maple Gioia
Maple Gioia serves as the Associate Director at Tessera Therapeutics, where she has worked since 2021. She has a strong background in biotechnology, with previous roles at several pharmaceutical companies and advanced degrees from Harvard University and SUNY Geneseo.
Work at Tessera Therapeutics
Maple Gioia has served as Associate Director at Tessera Therapeutics since 2021. In this role, she has contributed to the company's research initiatives, particularly focusing on innovative therapeutic approaches. Her responsibilities include overseeing research projects and ensuring alignment with the company's strategic goals in the biotechnology sector.
Previous Experience in Biotechnology
Prior to her current position, Maple Gioia worked at several prominent biotechnology companies. She was a Senior Research Associate at Momenta Pharmaceuticals from 2014 to 2016, where she contributed to research efforts in Cambridge, MA. Following this, she served as a Manager at bluebird bio from 2016 to 2021, also in Cambridge, Massachusetts. Earlier in her career, she held roles as a Research Associate at Alnylam Pharmaceuticals from 2008 to 2010 and as a Research Assistant at Genzyme Corporation from 2006 to 2008.
Education and Expertise
Maple Gioia holds a Master's degree in Extension Studies with a focus on Biotechnology from Harvard University, which she completed from 2018 to 2020. She also earned a Bachelor of Science degree in Biology from SUNY Geneseo, graduating in 2006. Her educational background supports her extensive expertise in assay development, particularly in RNA sequencing technologies.
Research Contributions and Technologies
Maple Gioia has played a key role in the development of RNA sequencing and single-cell RNA sequencing workstreams within research and exploratory clinical settings. She possesses extensive experience with 10X Genomics and Illumina sequencing platforms, which are critical for assay development. She actively keeps up-to-date with advancements in single-cell and sequencing technologies, ensuring her work remains at the forefront of the field.